慢性荨麻疹治疗中的患者价值观与偏好:系统综述
中等确定性证据提示患者高度重视症状快速改善、长期疗效及易于使用的口服或外用治疗。
要点
- 患者高度重视风团、瘙痒和肿胀的快速缓解与长期无症期
- 口服或外用治疗优于注射,输注最不受青睐
- 不良反应风险或严重程度增加时,患者更重视安全性与耐受性
核心结论
- 慢性荨麻疹患者高度重视风团、瘙痒和肿胀的即时与持续缓解,尤其看重长期无症期。
- 随着不良反应风险与严重程度增加,患者可能转为优先避免伤害与负担。
研究设计与样本
- 系统综述,检索MEDLINE、Embase、PsycINFO和CINAHL数据库,建库至2025年5月15日。
- 采用主题与归纳内容分析定性综合,并按GRADE-CERQual方法评定证据确定性。
主要发现
- 中等确定性证据:患者可能高度重视疾病体征和症状的快速改善(如2天至2周)。
- 中等确定性证据:患者重视长期疗效及易于准备、使用和自我管理的治疗。
- 中等确定性证据:口服或外用治疗优于注射,输注最不受青睐。
- 低确定性证据:患者可接受较小的可行性负担以换取快速持续缓解。
- 低确定性证据:不良反应风险或严重程度增加时,患者优先考虑安全性与耐受性。
临床怎么用
- 制定慢性荨麻疹管理推荐时可参考患者偏好,优先考虑快速起效、长期有效且易于自我管理的口服或外用方案。
- 与患者沟通时需权衡疗效与不良反应风险,风险升高时重视安全性与耐受性。
局限性
- 部分证据确定性较低(如关于可行性负担与安全性的权衡)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patient and caregiver values and preferences should inform clinical management. An update to the American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology's Joint Task Force on Practice Parameters guidelines on chronic urticaria (CU) plans to incorporate them; however, a systematic review of evidence on the values and preferences of patients with CU and their caregivers has not been previously available. OBJECTIVE: To synthesize patient and caregiver values and preferences regarding CU treatment options. EVIDENCE REVIEW: A systematic search was conducted of MEDLINE, Embase, PsycINFO, and CINAHL databases, from inception to May 15, 2025, for studies addressing patient and/or caregiver values and preferences for CU management. Paired reviewers independently screened studies, extracted data, and assessed risk of bias. Thematic and inductive content analysis was used to qualitatively synthesize findings and certainty of evidence was rated per the Grading of Recommendations Assessment, Development and Evaluation-Confidence in the Evidence from Reviews of Qualitative Research approach. FINDINGS: The search resulted in 18 studies addressing the values and preferences among 28 497 participants. Moderate certainty evidence showed that patients were likely to place a high value on rapid improvement (eg, 2 days to 2 weeks) of disease signs and symptoms, long-term effectiveness, and treatments that were easy to prepare, use, and self-manage-oral or topical treatments were favored over injections, with the least favored being infusions. Low certainty evidence suggested that patients accepted minor feasibility burdens for rapid and sustained symptom relief but prioritized safety and tolerability as the risk or severity of adverse effects (eg, kidney injury, vomiting) increased. CONCLUSIONS AND RELEVANCE: This systematic review suggests that patients with CU place high value on immediate and sustained hive, itch, and swelling relief, particularly long-term symptom-free periods, but may shift to prioritizing avoiding harms and burdens as the risk and severity of adverse effects increases. These findings may serve as a resource to improve the trustworthiness of recommendations and inform future CU management and research.
引用
- Chu X, Mubasher J, Chen L, et al. Patient Values and Preferences in Chronic Urticaria Treatment: A Systematic Review. JAMA Dermatol. 2025. PMID: 41060663. doi:10.1001/jamadermatol.2025.3663
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。